NAMPT and NAMPT-controlled NAD Metabolism in Vascular Repair

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 6, 2016, Pages 474-481

  Wang, Pei ^a   Li, Wen Lin ^a   Liu, Jian Min ^b   Miao, Chao Yu ^a,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

endothelial cell; Endothelial progenitor cell; NAD; vascular repair; vascular smooth muscle cell

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; CD38 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SIRTUIN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; ENDOTHELIAL PROGENITOR CELL; HUMAN; ISCHEMIA; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE CELL; VASCULAR SURGERY; ENDOTHELIUM CELL; METABOLISM; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANTIGENS, CD38; ENDOTHELIAL CELLS; ENDOTHELIAL PROGENITOR CELLS; MUSCLE, SMOOTH, VASCULAR; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION; SIRTUINS;

EID: 84975297457     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000332     Document Type: Review

References (118)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322.
2. Silvestre JS, Smadja DM, Levy BI. Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. Physiol Rev. 2013;93:1743-1802.
3. Silvestre JS, Mallat Z, Tedgui A, et al. Post-ischaemic neovascularization and inflammation. Cardiovasc Res. 2008;78:242-249.
4. Moraes F, Paye J, Mac Gabhann F, et al. Endothelial cell-dependent regulation of arteriogenesis. Circ Res. 2013;113:1076-1086.
5. Chang L, Noseda M, Higginson M, et al. Differentiation of vascular smooth muscle cells from local precursors during embryonic and adult arteriogenesis requires notch signaling. Proc Natl Acad Sci U S A. 2012; 109:6993-6998.
6. Tano JY, Schleifenbaum J, Gollasch M. Perivascular adipose tissue, potassium channels, and vascular dysfunction. Arterioscler Thromb Vasc Biol. 2014;34:1827-1830.
7. Siow RC, Churchman AT. Adventitial growth factor signalling and vascular remodelling: potential of perivascular gene transfer from the outside-in. Cardiovasc Res. 2007;75:659-668.
8. Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol. 2012;165:643-658.
9. Rich PR. The molecular machinery of Keilin's respiratory chain. Biochem Soc Trans. 2003;31:1095-1105.
10. Canto C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22:31-53.
11. Houtkooper RH, Canto C, Wanders RJ, et al. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31:194-223.
12. Koch-Nolte F, Haag F, Guse AH, et al. Emerging roles of NAD+ and its metabolites in cell signaling. Sci Signal. 2009;2:mr1.
13. Ruggieri S, Orsomando G, Sorci L, et al. Regulation of NAD biosynthetic enzymes modulates NAD-sensing processes to shape mammalian cell physiology under varying biological cues. Biochim Biophys Acta. 2015;1854:1138-1149.
14. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24:464-471.
15. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411-424.
16. Chini EN. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. Curr Pharm Des. 2009;15:57-63.
17. Kurnasov O, Goral V, Colabroy K, et al. NAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteria. Chem Biol. 2003;10:1195-1204.
18. Preiss J, Handler P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J Biol Chem. 1958;233:488-492.
19. Preiss J, Handler P. Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J Biol Chem. 1958;233:493-500.
20. Magni G, Amici A, Emanuelli M, et al. Enzymology of NAD+ synthesis. Adv Enzymol Relat Areas Mol Biol. 1999;73:135-182, xi.
21. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117: 495-502.
22. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32:3225-3234.
23. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431-1437.
24. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-430.
25. Dahl TB, Holm S, Aukrust P, et al. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr. 2012;32:229.
26. Garten A, Petzold S, Korner A, et al. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009;20:130-138.
27. Garten A, Schuster S, Penke M, et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11:535-546.
28. Revollo JR, Korner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6:363-375.
29. Nakahata Y, Sahar S, Astarita G, et al. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324:654-657.
30. Ramsey KM, Yoshino J, Brace CS, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009; 324:651-654.
31. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004;113:1318-1327.
32. Van Gool F, Galli M, Gueydan C, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med. 2009;15:206-210.
33. van der Veer E, Ho C, O'Neil C, et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem. 2007;282: 10841-10845.
34. Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130:1095-1107.
35. Wang P, Xu TY, Guan YF, et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81:370-380.
36. Zhao Y, Liu XZ, Tian WW, et al. Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury. CNS Neurosci Ther. 2014;20:539-547.
37. Yoon MJ, Yoshida M, Johnson S, et al. SIRT1-mediated eNAMPT secretion from adipose tissue regulates hypothalamic NAD(+) and function in mice. Cell Metab. 2015;21:706-717.
38. Li Y, Zhang Y, Dorweiler B, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem. 2008;283:34833-34843.
39. Audrito V, Serra S, Brusa D, et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;125:111-123.
40. Soncini D, Caffa I, Zoppoli G, et al. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem. 2014;289:34189-34204.
41. Lu LF, Yang SS, Wang CP, et al. Elevated visfatin/pre-B-cell colonyenhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis. 2009;18:354-359.
42. Kadoglou NP, Fotiadis G, Lambadiari V, et al. Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis. Peptides. 2014;57:12-16.
43. Kong Q, Xia M, Liang R, et al. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med J. 2014;55:383-387.
44. Yin CG, Jiang L, Tang B, et al. Prognostic significance of plasma visfatin levels in patients with ischemic stroke. Peptides. 2013;42:101-104.
45. Lu LF, Wang CP, Yu TH, et al. Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction. Cytokine. 2012;57:74-80.
46. Hung WC, Yu TH, Hsu CC, et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute STelevation myocardial infarction. Clin Invest Med. 2015;38:E100-E109.
47. Mazaherioun M, Hosseinzadeh-Attar MJ, Janani L, et al. Elevated serum visfatin levels in patients with acute myocardial infarction. Arch Iran Med. 2012;15:688-692.
48. Kaja S, Shah AA, Haji SA, et al. Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions. Clin Ophthalmol. 2015;9:611-618.
49. Ucak A, Temizkan V, Sen H, et al. The effect of serum, intestinal and peritoneal visfatin levels on early diagnosis of acute mesenteric ischemia [published online ahead of print March 6, 2015]. Int Angiol. doi: http://dx.doi.org/10.1016/j.amjcard.2015.01.375.
50. Wang P, Xu TY, Guan YF, et al. Nicotinamide phosphoribosyl transferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol. 2011;69:360-374.
51. Wang P, Guan YF, Du H, et al. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy. 2012;8:77-87.
52. Wang P, Xu TY, Wei K, et al. ARRB1/beta-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia. Autophagy. 2014;10:1535-1548.
53. Wang P, Guan YF, Li WL, et al. Nicotinamide phosphoribosyltransferase facilitates post-stroke angiogenesis. CNS Neurosci Ther. 2015;21: 475-477.
54. Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio-cerebro-vascular disease. J Cardiovasc Pharmacol. 2012;59:1-9.
55. Hsu CP, Oka S, Shao D, et al. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009;105:481-491.
56. Lim SY, Davidson SM, Paramanathan AJ, et al. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med. 2008;12:1395-1403.
57. Yamamoto T, Byun J, Zhai P, et al. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One. 2014;9:e98972.
58. Wang P, Du H, Zhou CC, et al. Intracellular NAMPT-NAD+-SIRT1 cascade improves post-ischaemic vascular repair by modulating Notch signalling in endothelial progenitors. Cardiovasc Res. 2014;104: 477-488.
59. Lovren F, Pan Y, Shukla PC, et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab. 2009;296:E1440-E1449.
60. Kim SR, Bae SK, Choi KS, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357:150-156.
61. Bae YH, Bae MK, Kim SR, et al. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochem Biophys Res Commun. 2009;379:206-211.
62. Bae YH, Park HJ, Kim SR, et al. Notch1 mediates visfatin-induced FGF-2 up-regulation and endothelial angiogenesis. Cardiovasc Res. 2011;89:436-445.
63. Kim JY, Bae YH, Bae MK, et al. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta. 2009;1793:1759-1767.
64. Kim SR, Jung YH, Park HJ, et al. Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells. Biochem Biophys Res Commun. 2012;418: 662-668.
65. Adya R, Tan BK, Punn A, et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78:356-365.
66. Adya R, Tan BK, Chen J, et al. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis. 2009;205: 113-119.
67. Xiao J, Xiao ZJ, Liu ZG, et al. Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. Diabetes Metab Res Rev. 2009;25: 242-249.
68. Park JW, Kim WH, Shin SH, et al. Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway. Biochim Biophys Acta. 2011;1813:763-771.
69. Borradaile NM, Pickering JG. Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell. 2009;8:100-112.
70. Borradaile NM, Pickering JG. Polyploidy impairs human aortic endothelial cell function and is prevented by nicotinamide phosphoribosyltransferase. Am J Physiol Cell Physiol. 2010;298: C66-C74.
71. Kato H, Ito E, Shi W, et al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res. 2010;16:898-911.
72. Cagnetta A, Cea M, Calimeri T, et al. Intracellular NAD(+) depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013;122: 1243-1255.
73. Neubauer K, Misa IB, Diakowska D, et al. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1beta, and anemia. Biomed Res Int. 2015; 2015:523930.
74. Wang Y, Yuan Y, Jiang H. Serum and vitreous levels of visfatin in patients with diabetic retinopathy. Med Sci Monit. 2014;20: 2729-2732.
75. Takebayashi K, Suetsugu M, Wakabayashi S, et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56:451-458.
76. Lacolley P, Regnault V, Nicoletti A, et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012;95:194-204.
77. Vallejo S, Romacho T, Angulo J, et al. Visfatin impairs endotheliumdependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One. 2011; 6:e27299.
78. Yamawaki H, Hara N, Okada M, et al. Visfatin causes endotheliumdependent relaxation in isolated blood vessels. Biochem Biophys Res Commun. 2009;383:503-508.
79. van der Veer E, Nong Z, O'Neil C, et al. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005;97: 25-34.
80. Ho C, van der Veer E, Akawi O, et al. SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett. 2009;583:3081-3085.
81. Huang P, Riordan SM, Heruth DP, et al. A critical role of nicotinamide phosphoribosyltransferase in human telomerase reverse transcriptase induction by resveratrol in aortic smooth muscle cells. Oncotarget. 2015;6:10812-10824.
82. Yin H, van der Veer E, Frontini MJ, et al. Intrinsic directionality of migrating vascular smooth muscle cells is regulated by NAD(+) biosynthesis. J Cell Sci. 2012;125:5770-5780.
83. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
84. Krenning G, van Luyn MJ, Harmsen MC. Endothelial progenitor cellbased neovascularization: implications for therapy. Trends Mol Med. 2009;15:180-189.
85. Sun Y, Chen S, Song G, et al. Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action. Int J Mol Med. 2012;30:622-628.
86. Chen S, Sun L, Gao H, et al. Visfatin and oxidative stress influence endothelial progenitor cells in obese populations. Endocr Res. 2015;40: 83-87.
87. Fulco M, Cen Y, Zhao P, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPKmediated regulation of Nampt. Dev Cell. 2008;14:661-673.
88. Li Y, He X, He J, et al. Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals. J Bone Miner Res. 2011;26:2656-2664.
89. Li Y, He J, He X, et al. Nampt expression increases during osteogenic differentiation of multi-and omnipotent progenitors. Biochem Biophys Res Commun. 2013;434:117-123.
90. Albiero M, Poncina N, Tjwa M, et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes. 2014;63:1353-1365.
91. Wang YQ, Cao Q, Wang F, et al. SIRT1 protects against oxidative stress-induced endothelial progenitor cells apoptosis by inhibiting FOXO3a via FOXO3a ubiquitination and degradation. J Cell Physiol. 2015; 230:2098-2107.
92. Zeng H, Li L, Chen JX. Loss of Sirt3 limits bone marrow cell-mediated angiogenesis and cardiac repair in post-myocardial infarction. PLoS One. 2014;9:e107011.
93. Cardus A, Uryga AK, Walters G, et al. SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence. Cardiovasc Res. 2013;97:571-579.
94. Zhang RY, Qin Y, Lv XQ, et al. A fluorometric assay for highthroughput screening targeting nicotinamide phosphoribosyltransferase. Anal Biochem. 2011;412:18-25.
95. Xu TY, Zhang SL, Dong GQ, et al. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. Sci Rep. 2015;5:10043.
96. Wang X, Xu TY, Liu XZ, et al. Discovery of novel inhibitors and fluorescent probe targeting NAMPT. Sci Rep. 2015;5:12657.
97. Sampath D, Zabka TS, Misner DL, et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol Ther. 2015;151:16-31.
98. Wang G, Han T, Nijhawan D, et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell. 2014;158:1324-1334.
99. Walker AK, Rivera PD, Wang Q, et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2015;20:500-508.
100. Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142:39-51.
101. Latchney SE, Jaramillo TC, Rivera PD, et al. Chronic P7C3 treatment restores hippocampal neurogenesis. Neurosci Lett. 2015;591:86-92.
102. Zhao Y, Guan YF, Zhou XM, et al. Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferasenicotinamide adenine dinucleotide Cascade. Stroke. 2015;46:1966-1974.
103. Canto C, Houtkooper RH, Pirinen E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15:838-847.
104. Yoshino J, Mills KF, Yoon MJ, et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-and ageinduced diabetes in mice. Cell Metab. 2011;14:528-536.
105. Brown KD, Maqsood S, Huang JY, et al. Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 2014;20:1059-1068.
106. Tummala KS, Gomes AL, YilmazM, et al. Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer cell. 2014;26:826-839.
107. Song J, Ke SF, Zhou CC, et al. Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation. J Gerontol A Biol Sci Med Sci. 2014;69:44-57.
108. Ponugoti B, Xu F, Zhang C, et al. FOXO1 promotes wound healing through the up-regulation of TGF-beta1 and prevention of oxidative stress. J Cell Biol. 2013;203:327-343.
109. Hughes-Large JM, Pang DK, Robson DL, et al. Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity. Atherosclerosis. 2014;237:696-704.
110. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30:351-367.
111. Esposito E, Impellizzeri D, Mazzon E, et al. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. J Neuroinflammation. 2012;9:66.
112. Bruzzone S, Fruscione F, Morando S, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One. 2009;4:e7897.
113. Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21: 2644-2658.
114. Guarani V, Deflorian G, Franco CA, et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature. 2011;473:234-238.
115. Xie M, Liu M, He CS. SIRT1 regulates endothelial Notch signaling in lung cancer. PLoS One. 2012;7:e45331.
116. Etich J, Bergmeier V, Frie C, et al. PECAM1(+)/Sca1(+)/CD38(+) vascular cells transform into myofibroblast-like cells in skin wound repair. PLoS One. 2013;8:e53262.
117. Mathews MT, Berk BC. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol. 2008;28: 711-717.
118. Choi SK, Galan M, Kassan M, et al. Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus. Hypertension. 2012;59:1060-1068.